BCAL Diagnostics (ASX:BDX) - Share price, News & Analysis

BDX fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

BDX Overview

BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer.

Risk Analysis

Revenue has declined by 37.7% over the past year

Makes less than USD$1m in revenue (A$275K)

Volatile share price over the past 3 months

Does not have a meaningful market cap (A$34M)

BCAL Diagnostics Competitors

BARD1 Life Sciences

ASX:BD1

AU$99.7m

Price History & Performance

Summary of all time highs, changes and price drops for BCAL Diagnostics
Historical stock prices
Current Share Price	AU$0.17
52 Week High	AU$0.14
52 Week Low	AU$0.28
Beta	0
1 Month Change	0%
3 Month Change	-21.43%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-34.00%

Shareholder Returns

	BDX	AU Biotechs	AU Market
7D	3.1%	1.1%	1.7%
1Y	n/a	1.7%	20.2%

Return vs Industry: Insufficient data to determine how BDX performed against the Australian Biotechs industry.

Return vs Market: Insufficient data to determine how BDX performed against the Australian Market.

Price Volatility

Is BDX's price volatile compared to industry and market?
BDX volatility
BDX Beta	0
Industry Beta	1.62
Market Beta	1

Stable Share Price: BDX is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: Insufficient data to determine BDX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2010	n/a	n/a	https://www.bcaldiagnostics.com

BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vesicles from a patient's plasma or blood sample to diagnose the presence of breast cancer cells in a patient’s body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

BCAL Diagnostics Fundamentals Summary

How do BCAL Diagnostics's earnings and revenue compare to its market cap?
BDX fundamental statistics
Market Cap	AU$34.13m
Earnings (TTM)	-AU$1.52m
Revenue (TTM)	AU$275.25k

124.1x

P/S Ratio

-22.4x

P/E Ratio

Is BDX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
BDX income statement (TTM)
Revenue	AU$275.25k
Cost of Revenue	AU$0
Gross Profit	AU$275.25k
Expenses	AU$1.80m
Earnings	-AU$1.52m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)	-0.0074
Gross Margin	100.00%
Net Profit Margin	-554.03%
Debt/Equity Ratio	0.0%

How did BDX perform over the long term?

See historical performance and comparison

Valuation

Is BCAL Diagnostics undervalued compared to its fair value and its price relative to the market?

9.47x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate BDX's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate BDX's fair value to establish if it is undervalued.

Price To Earnings Ratio

PE vs Industry: BDX is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.

PE vs Market: BDX is unprofitable, so we can't compare its PE Ratio to the Australian market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate BDX's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: BDX is overvalued based on its PB Ratio (9.5x) compared to the AU Biotechs industry average (4.8x).

Future Growth

How is BCAL Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

11.4%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BCAL Diagnostics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Past Performance

How has BCAL Diagnostics performed over the past 5 years?

-119.0%

Last years earnings growth

Earnings and Revenue History

Quality Earnings: BDX is currently unprofitable.

Growing Profit Margin: BDX is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if BDX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare BDX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BDX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).

Return on Equity

High ROE: BDX has a negative Return on Equity (-42.28%), as it is currently unprofitable.

Financial Health

How is BCAL Diagnostics's financial position?

Financial Position Analysis

Short Term Liabilities: BDX's short term assets (A$4.1M) exceed its short term liabilities (A$525.6K).

Long Term Liabilities: BDX's short term assets (A$4.1M) exceed its long term liabilities (A$10.0).

Debt to Equity History and Analysis

Debt Level: BDX is debt free.

Reducing Debt: BDX had no debt 5 years ago.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BDX has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: BDX has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 19.5% each year.

Dividend

What is BCAL Diagnostics's current dividend yield, its reliability and sustainability?

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BDX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BDX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BDX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BDX's dividend payments have been increasing.

Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of BDX's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.

Next Steps

Explore strong dividend paying companies in the Pharmaceuticals & Biotech industry.

Management

How experienced are the management team and are they aligned to shareholders interests?

0.7yrs

Average board tenure

CEO

BCAL Diagnostics has no CEO, or we have no data on them.

Board Members

Experienced Board: BDX's board of directors are not considered experienced ( 0.7 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: BDX only recently listed within the past 12 months.

Data	Last Updated (UTC time)
Company Analysis	2021/10/20 15:34
End of Day Share Price	2021/10/20 00:00
Earnings	2021/06/30
Annual Earnings	2021/06/30

Market Cap

7D

1Y

Updated

Data